NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Royal Orchid Hotels Limited (ROHL) has announced the opening of Regenta Devarayah in Tirupati, a major pilgrimage destination in Andhra Pradesh. The new 4-star property features 56 rooms, including 2 Presidential Suites, and is strategically located near the Tirumala Venkateswara Temple. A significant operational highlight is its 220 kW vertical solar installation, which provides 80% of the hotel's power consumption. This launch is part of the company's 'Vision 2030' strategy to capitalize on the growing demand for spiritual and leisure tourism.
முக்கிய அம்சங்கள்
Launch of a new 56-key upscale 4-star property in the high-footfall pilgrimage hub of Tirupati.Strategic location 2 km from Tirupati Railway Station and 15 km from Renigunta International Airport.First hotel in Andhra Pradesh to use Vertical Solar (220 kW capacity), meeting 80% of its power needs.Includes banquet facilities for up to 200 people and 3 board rooms to cater to MICE and social events.The property is part of ROHL's 'Vision 2030' expansion plan to strengthen its presence in key Indian markets.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in ROHL's asset-light or subsidiary-led expansion, specifically targeting the resilient spiritual tourism segment. Monitor the company's upcoming quarterly results for improvements in RevPAR and occupancy driven by such new additions.
India Power Corp (DPSCLTD) Concludes 1st Committee of Creditors Meeting Under CIRP
India Power Corporation Limited (IPCL) held its first Committee of Creditors (CoC) meeting on June 12, 2026, following the initiation of the Corporate Insolvency Resolution Process (CIRP) by NCLT Hyderabad on May 15, 2026. The meeting, conducted via video conferencing from 11:30 AM to 1:30 PM, involved deliberations on agenda items under the supervision of the Interim Resolution Professional. This follows the company's admission into insolvency, marking a critical phase in its financial restructuring and debt resolution.
முக்கிய அம்சங்கள்
First CoC meeting held on June 12, 2026, following the NCLT Hyderabad Bench-I order dated May 15, 2026.The meeting was conducted via Video Conferencing for a duration of 2 hours (11:30 AM to 1:30 PM IST).Ms. Sreenivasa Mano Ranjani is acting as the Interim Resolution Professional (IRP) for the process.Agenda items and matters placed before the Committee were deliberated upon by the financial creditors.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as CIRP proceedings often result in significant equity dilution or delisting of the company. Closely monitor future CoC updates regarding the resolution plan and potential recovery for stakeholders.
Alembic Pharma Receives USFDA Final Approval for Tretinoin Cream; Market Size $76 Million
Alembic Pharmaceuticals has received final USFDA approval for Tretinoin Cream USP, 0.05%, used for treating acne vulgaris. The product is a generic equivalent of Retin-A Cream and targets a US market size estimated at $76 million for the twelve months ending March 2026. This approval brings Alembic's cumulative total to 242 ANDA approvals, including 222 final approvals. This development strengthens the company's dermatological portfolio in the US market.
முக்கிய அம்சங்கள்
Received USFDA final approval for Tretinoin Cream USP, 0.05%, indicated for acne vulgaris.The product addresses an estimated annual market size of US$ 76 million according to IQVIA data.The approved ANDA is therapeutically equivalent to the reference listed drug Retin-A Cream by Bausch Health.Alembic now holds a cumulative total of 242 ANDA approvals (222 final and 20 tentative).
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's product launch timeline and market share gains in the US generics space. This approval adds a steady revenue stream to the US business, which remains a key growth driver for Alembic.
Emami Increases Stake in IncNut Digital to 60.00% Following Share Acquisition
Emami Limited has acquired an additional 1,064 equity shares in IncNut Digital Private Limited on June 11, 2026. This transaction has increased Emami's total shareholding in the company from 59.69% to 60.00%. The acquisition was completed as per the terms of a previously disclosed Share Subscription and Purchase Agreement. This move further consolidates Emami's controlling interest in the digital-first beauty and wellness platform.
முக்கிய அம்சங்கள்
Acquired 1,064 equity shares of IncNut Digital Private Limited on June 11, 2026.Total stake in IncNut Digital increased from 59.69% to 60.00%.The acquisition follows the terms of the Share Subscription and Purchase Agreement dated May 7, 2026.Consolidates Emami's presence in the digital media and e-commerce beauty segment.
👀 கவனிக்க வேண்டியவை
No immediate action is required as this is a marginal 0.31% increase in stake within an existing subsidiary. Investors should monitor how Emami leverages IncNut's digital capabilities to drive growth in its D2C portfolio.
LTM Launches AI 1000 Initiative to Train 1,000+ AI-Certified Forward Deployed Engineers
LTM Limited has launched 'AI 1000', a strategic workforce transformation initiative to develop over 1,000 AI-certified engineers, specifically focusing on the high-demand 'Forward Deployed Engineer' (FDE) role. The program is anchored by a new Center of Excellence (CoE) and utilizes a proprietary AI Readiness Index to identify talent within its 87,000-strong workforce. This initiative builds on LTM's existing foundation of 24,000 AI-trained associates and 15,000 external certifications to drive quantifiable ROI for enterprise clients. The move signals a shift toward high-value, AI-native service delivery models.
முக்கிய அம்சங்கள்
Launched AI 1000 initiative to develop a pool of 1,000+ AI-certified Forward Deployed Engineers (FDEs).Established a dedicated Center of Excellence (CoE) using a four-stage model: Identify, Enable, Deploy, and Govern.Leverages a proprietary AI Readiness Index to select high-potential talent from 87,000 total employees.Builds on a foundation of 6.5 million learning hours and 24,000 already AI-trained associates.Focuses on bridging the gap between technical LLM/SLM knowledge and business-specific ROI outcomes.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward margin expansion through higher-value AI consulting and engineering services. Monitor future quarterly earnings for improvements in revenue per employee and the scale of AI-led contract wins.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
CARE Reaffirms 'CARE A1+' Rating for Alembic Pharma's Rs 1,100 Cr Commercial Paper
CARE Ratings Limited has reaffirmed its 'CARE A1+' credit rating for Alembic Pharmaceuticals Limited's Commercial Paper program. The rating applies to a total facility amount of Rs 1,100.00 Crores as of June 11, 2026. This rating is the highest short-term credit rating possible, indicating a very strong degree of safety regarding timely payment of financial obligations. The reaffirmation suggests that the company maintains a stable financial profile and adequate liquidity to service its short-term debt.
முக்கிய அம்சங்கள்
CARE Ratings Limited reaffirmed the 'CARE A1+' rating for the company's Commercial Paper.The rating covers a total facility amount of Rs 1,100.00 Crores.The 'A1+' rating signifies the highest degree of safety for short-term debt instruments.The rating action was confirmed via a CARE Ratings press release dated June 11, 2026.
👀 கவனிக்க வேண்டியவை
Investors can remain confident in the company's short-term creditworthiness and liquidity position. No immediate portfolio changes are necessary as this is a reaffirmation of existing financial strength.
Promoter Khandepar Investments Acquires 3,00,000 Shares of Ravindra Energy via Open Market
Khandepar Investments Private Limited, a promoter entity of Ravindra Energy Limited, has increased its stake by purchasing 3,00,000 equity shares from the open market. The acquisition took place between June 8 and June 10, 2026, for a total consideration of approximately ₹2.16 crores. Such open market purchases by promoters are typically viewed as a sign of confidence in the company's future performance and intrinsic value.
முக்கிய அம்சங்கள்
Promoter group entity Khandepar Investments Private Limited acquired 3,00,000 equity shares.The shares were purchased through open market transactions between June 8, 2026, and June 10, 2026.The total value of the acquisition is approximately ₹2,16,00,000 (₹2.16 Crores).The disclosure was filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Promoter buying from the open market is a bullish indicator; investors should monitor if this trend of stake consolidation continues as it reflects management's confidence.
Alembic Pharma Receives USFDA Tentative Approval for Larotrectinib; Sole First-to-File Status
Alembic Pharmaceuticals has received tentative USFDA approval for Larotrectinib Capsules (25 mg and 100 mg), used for treating solid tumors. The company is the sole first applicant to file a Paragraph IV certification, which may grant it 180 days of generic marketing exclusivity in the U.S. upon final approval. The market size for this product is estimated at US$ 91 million for the twelve months ending March 2026. This milestone brings Alembic's total USFDA approvals to 241, including 20 tentative approvals.
முக்கிய அம்சங்கள்
Received USFDA tentative approval for Larotrectinib Capsules (25 mg and 100 mg), a generic version of Vitrakvi.Identified as the sole first applicant with a Paragraph IV certification, potentially securing 180 days of exclusivity.Target market size for the product is approximately US$ 91 million as of March 2026.Cumulative USFDA ANDA approvals reached 241, consisting of 221 final and 20 tentative approvals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from tentative to final approval, as the sole first-to-file status provides a significant competitive advantage and high-margin potential during the 180-day exclusivity period.
Promoter Group Aksara Commercial Sells 3.39 Lakh Shares of DPSCLTD Amid CIRP Proceedings
India Power Corporation Limited (formerly DPSC Limited) is currently undergoing the Corporate Insolvency Resolution Process (CIRP) following an NCLT order dated May 15, 2026. During this period, Aksara Commercial Private Limited, a member of the promoter group, sold 3,39,901 equity shares via the open market on June 8 and 9, 2026. The transaction, valued at approximately Rs. 25.80 lakhs, reduced their stake from 6.26% to 6.23%. The company's board remains suspended, with operations managed by an Interim Resolution Professional.
முக்கிய அம்சங்கள்
Promoter group entity Aksara Commercial sold 3,39,901 shares worth Rs. 25.80 lakhs in the open market.The sale resulted in a marginal reduction of the promoter group's holding from 6.26% to 6.23%.The company is officially under CIRP following an application admitted under Section 7 of the IBC by NCLT Hyderabad.Powers of the Board of Directors are currently suspended, and the company is under the authority of an IRP.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency proceedings, which often leads to significant equity erosion or delisting. The sale of shares by a promoter group entity during the CIRP phase is a negative signal.
LTTS Partners with Databricks to Deliver Industrial AI Solutions for Asset-Intensive Industries
L&T Technology Services (LTTS) has announced a strategic go-to-market partnership with Databricks to co-develop Industrial AI solutions for asset-intensive sectors including Energy and Petrochemicals. The collaboration aims to transform complex plant data into 'Engineering Intelligence' by leveraging LTTS's experience across 600+ major plants and Databricks' data platform. This initiative targets high-growth areas such as predictive asset reliability and emissions optimization within LTTS's Sustainability segment. As of March 2026, LTTS maintains a strong market position with 69 Fortune 500 clients and over 23,800 employees.
முக்கிய அம்சங்கள்
Strategic partnership with Databricks to deliver Industrial AI and Engineering Intelligence solutions globally.Focuses on asset-intensive industries including Energy, Petrochemicals, and Discrete Manufacturing.Leverages LTTS's domain expertise across more than 600 major plants worldwide.Solutions to cover Predictive Asset Reliability, Energy & Emissions Optimization, and Quality Intelligence.LTTS reports a client base of 69 Fortune 500 companies and 57 top ER&D firms as of March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move to strengthen LTTS's AI and Sustainability offerings, potentially driving higher-margin digital engineering contracts. Monitor for future deal wins specifically attributed to this Databricks collaboration in the Energy and Industrial segments.
HCLTech Shareholders Approve Appointment of Kimsuka Narsimhan as Independent Director with 99.76% Votes
HCL Technologies shareholders have overwhelmingly approved the appointment of Ms. Kimsuka Narsimhan as an Independent Director via a postal ballot. Out of 252.49 crore total valid votes cast, 99.7561% were in favor of the special resolution. Institutional investors showed strong support with 99.30% voting in favor, while the promoter group voted 100% in favor. The appointment is effective from June 10, 2026, strengthening the company's board governance.
முக்கிய அம்சங்கள்
Special resolution for the appointment of Ms. Kimsuka Narsimhan as Independent Director passed with 99.7561% majority.A total of 252.49 crore valid votes were cast during the e-voting period which concluded on June 10, 2026.Public Institutional investors cast 87.22 crore votes, with 99.30% supporting the appointment.Promoter and Promoter Group cast 165.18 crore votes, all of which were in favor of the resolution.The resolution was conducted through a remote e-voting process as per the Scrutinizer's report by Nityanand Singh & Co.
👀 கவனிக்க வேண்டியவை
No immediate action is required as this is a standard governance procedure. The high approval rate from both institutional and retail investors reflects strong confidence in the company's leadership and board selection.
Indiabulls Limited to Raise ₹1,000.07 Crore via Preferential Issue of Convertible Warrants
Indiabulls Limited has scheduled an EGM on July 2, 2026, to seek shareholder approval for a ₹1,000.07 crore fundraise through the issuance of 51.55 crore convertible warrants. The warrants are priced at ₹19.40 each, with the Promoter Group (Phanes Limited and Hermes Limited) contributing ₹709.07 crore and Non-Promoter entities contributing ₹291 crore. Investors are required to pay 25% of the issue price upfront, with the remaining 75% payable within 18 months upon conversion into equity shares. This move is expected to significantly strengthen the company's capital base and indicates strong promoter backing.
முக்கிய அம்சங்கள்
Preferential issue of 51,55,00,000 unlisted warrants to raise a total of ₹1,000.07 crore.Issue price set at ₹19.40 per warrant, including a premium of ₹17.40, based on the relevant date of June 2, 2026.Promoter group entities to subscribe to 36,55,00,000 warrants, representing approximately 12.75% of post-issue diluted capital.Non-promoter entities EBISU Global and Nyaasa Global to subscribe to 15,00,00,000 warrants.Warrants are convertible into equity shares on a 1:1 basis within an 18-month exercise period.
👀 கவனிக்க வேண்டியவை
Investors should view the substantial promoter participation as a vote of confidence in the company's future prospects, though they should remain mindful of the potential ~18% equity dilution upon full conversion.
Health X to Demerge Finance Business into MRL; 1:3 Share Swap and Listing Planned
Health X Platform Limited has announced a composite scheme to simplify its corporate structure by separating its healthcare and financial services businesses. The financial business will be demerged into Microsec Resources Private Limited (MRL), with shareholders receiving 1 share of MRL for every 3 shares held in Health X. Additionally, Sastasundar Healthbuddy Limited will merge into Health X, increasing the public shareholding in Health X from 25.93% to 41.57%. The scheme aims to unlock value and provide operational independence for both segments, with MRL slated for listing on BSE and NSE.
முக்கிய அம்சங்கள்
Demerger of finance business into MRL with a 1:3 share swap ratio for Health X shareholders.MRL to be converted to a public company and listed on BSE and NSE for liquidity.Merger of SHBL into Health X, resulting in the issuance of 85,12,168 new shares to SHBL public holders.Health X public shareholding to significantly expand from 25.93% to 41.57% post-scheme.Expected implementation timeline of 12-14 months, targeting completion by July 2027.
👀 கவனிக்க வேண்டியவை
Investors should maintain their positions to benefit from the value unlocking of the financial services business and the consolidation of the healthcare segment. Monitor the NCLT and regulatory approval process over the next year for any timeline shifts.
UltraTech Cement to Acquire 13.99% Stake in FPEL Services for ₹12.09 Crore
UltraTech Cement and its subsidiary, The India Cements Limited, have entered into agreements to acquire equity stakes in FPEL Services Private Limited, a renewable energy SPV. UltraTech will invest ₹12.09 crore for a 13.99% stake, while India Cements will invest ₹10.78 crore for a 12.48% stake. The acquisition is designed to secure 15.70 MW of wind power for plants in Tamil Nadu under a captive power arrangement. This strategic move aims to optimize energy costs and fulfill green energy regulatory requirements.
முக்கிய அம்சங்கள்
UltraTech Cement to invest ₹12.089 crore for a 13.99% equity stake in FPEL Services.Subsidiary The India Cements Limited to invest ₹10.78 crore for an additional 12.48% stake.The SPV will supply 15.70 MW AC wind power to the company's Tamil Nadu plants on a captive basis.The acquisition is expected to be completed within 180 days from the execution of the agreement.Investment is aimed at meeting green energy needs and optimizing long-term power costs.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive strategic move towards ESG compliance and cost efficiency, though the investment size is small relative to the company's total valuation. No immediate portfolio changes are necessary based on this routine infrastructure investment.
Presidential Approval Granted for Merger of REC Limited into PFC
REC Limited has received official Presidential approval via the Ministry of Power for its proposed merger into Power Finance Corporation Limited (PFC). This follows the REC Board's decision on May 16, 2026, to reserve the proposal for such approval. The Ministry of Power conveyed the Competent Authority's clearance on June 10, 2026, marking a significant regulatory milestone in the consolidation of these two Maharatna power-sector financiers.
முக்கிய அம்சங்கள்
Ministry of Power conveyed Presidential approval for the REC-PFC merger on June 10, 2026.The merger proposal was previously moved by the Board of Directors on May 16, 2026.The consolidation involves two major Maharatna PSUs specializing in power sector infrastructure lending.The approval clears a major sovereign hurdle for the completion of the merger process.
👀 கவனிக்க வேண்டியவை
Investors should watch for the announcement of the share swap ratio and the effective date of the merger. Existing REC shareholders will eventually receive PFC shares, so monitoring PFC's stock performance and valuation is now equally critical.
Health X Platform Announces Restructuring: 1:3 Demerger Ratio and Merger of Healthbuddy Unit
Health X Platform Limited (formerly Sastasundar Ventures) has approved a composite scheme of arrangement to separate its financial and healthcare businesses. The financial services division, which contributed 1.10% (₹1,519.05 lakhs) to consolidated turnover in FY26, will be demerged into Microsec Resources Private Limited, with shareholders receiving 1 share for every 3 shares held in Health X. Additionally, the company will merge its subsidiary Sastasundar Healthbuddy Limited into itself to consolidate healthcare operations, issuing 85.12 lakh shares to minority holders. The appointed date for this restructuring is April 1, 2026.
முக்கிய அம்சங்கள்
Demerger ratio set at 1 equity share of Microsec Resources for every 3 equity shares held in Health X Platform.Amalgamation of Sastasundar Healthbuddy into Health X involves issuing 85,12,168 new shares for 45,75,830 shares held by non-promoters.The demerged financial services undertaking reported a turnover of ₹1,519.05 lakhs against a consolidated total of ₹1,37,753.67 lakhs in FY26.Health X Platform (Consolidated) reported total assets of ₹93,576.87 lakhs as of March 31, 2026.The scheme aims to unlock value by creating a focused entity for financial services and streamlining the healthcare supply chain.
👀 கவனிக்க வேண்டியவை
Investors should maintain their positions to benefit from the value unlocking of the separate financial services entity and the simplified corporate structure of the core healthcare business. Monitor the NCLT approval process and the record date for the share entitlement.
Health X Platform Approves Major Restructuring; 1:3 Demerger Ratio for Financial Services
Health X Platform Limited (HEALTHX) has approved a composite scheme of arrangement involving a demerger and multiple amalgamations. The company will demerge its financial services division into Microsec Resources Private Limited, with shareholders receiving 1 share of the new entity for every 3 shares held in HEALTHX. Simultaneously, Sastasundar Healthbuddy Limited (SHBL) will merge into HEALTHX, consolidating the healthcare business. The demerged financial division contributed 1.10% (₹1,519.05 lakhs) to the total consolidated turnover of ₹1,37,753.67 lakhs in FY26.
முக்கிய அம்சங்கள்
Shareholders to receive 1 share of Microsec Resources for every 3 shares held in Health X Platform.Health X to issue 85,12,168 equity shares to minority shareholders of Sastasundar Healthbuddy Limited (SHBL) for its merger.The demerged financial services undertaking reported a turnover of ₹1,519.05 lakhs, representing 1.10% of consolidated revenue.Consolidated assets of Health X Platform stood at ₹93,576.87 lakhs as of March 31, 2026.The appointed date for the scheme is April 1, 2026, subject to NCLT, RBI, and SEBI approvals.
👀 கவனிக்க வேண்டியவை
Investors should maintain their positions to benefit from the potential value unlocking of the financial services business and a more focused healthcare entity. Monitor the timeline for NCLT approvals and the eventual listing of the demerged entity.
3i Infotech Secures ₹37.05 Crore IT Services Order from HPCL for 3 Years
3i Infotech Limited has received a significant purchase order from Hindustan Petroleum Corporation Limited (HPCL) for providing Facility Management Services (FMS). The contract is valued at approximately ₹37.05 crores (exclusive of taxes) and spans a duration of three years. The scope includes comprehensive IT infrastructure support, skilled manpower, and managed services across HPCL's PAN India locations, including R&D centers and refineries. This deal provides steady revenue visibility for the company's IT services segment over the medium term.
முக்கிய அம்சங்கள்
Total contract value of approximately ₹37.05 crores excluding applicable taxes.The order is awarded by Hindustan Petroleum Corporation Limited (HPCL), a major domestic entity.Execution period is set for 3 years, providing long-term service revenue.Scope covers IT Facility Management Services, including server, endpoint, and digital infrastructure support across multiple Indian locations.The engagement involves supporting critical business operations at HPCL's Corporate R&D Centre and Visakh Refinery.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain margins on this contract and look for further order wins in the PSU sector to drive growth.
Loyal Textile Mills CEO N Srinivasan Resigns; ED M.E. Manivannan to Lead Operations
Loyal Textile Mills Limited has announced that Mr. N Srinivasan, the Chief Executive Officer, has resigned due to personal reasons effective June 30, 2026. The Board has promptly entrusted the company's overall management and operations to Mr. M.E. Manivannan, an existing Executive Director and Key Managerial Personnel. This internal transition is intended to ensure business continuity and operational stability. The outgoing CEO has confirmed there are no other material reasons for his departure beyond personal ones.
முக்கிய அம்சங்கள்
CEO Mr. N Srinivasan to step down effective June 30, 2026, after resigning on June 9, 2026.Executive Director Mr. M.E. Manivannan (DIN: 02229808) appointed to oversee overall management.The Board and Nomination and Remuneration Committee approved the transition via circular resolution on June 10, 2026.The company confirmed no material reasons for resignation other than personal grounds.
👀 கவனிக்க வேண்டியவை
Investors should watch for any shifts in strategic direction under the new leadership but can remain neutral as the transition is internal and orderly.
India Power Corp (DPSCLTD) Credit Rating Downgraded to 'D' (Default) Following CIRP Admission
Brickwork Ratings has downgraded India Power Corporation Limited's (formerly DPSC Ltd) bank loan facilities totaling ₹106.98 crores to 'BWR D' (Default). This action follows the company's admission into the Corporate Insolvency Resolution Process (CIRP) by the NCLT Hyderabad Bench on May 15, 2026, and a confirmed default on interest payments for May 2026. The company's board is currently suspended, and it reported a massive net loss of ₹229.76 crores for FY26. A statutory moratorium is now in place as the Committee of Creditors prepares for its first meeting on June 12, 2026.
முக்கிய அம்சங்கள்
Long-term rating for ₹102.83 crore bank loans downgraded from BWR BB to BWR D.Short-term rating for ₹4.15 crore facilities downgraded from BWR A4 to BWR D.Company admitted to CIRP following a petition by State Bank of India (SBI) regarding a ₹500.48 crore default claim.FY26 financial performance deteriorated sharply with a net loss of ₹229.76 crores versus a profit of ₹4.22 crores in FY25.Tangible Net Worth dropped significantly from ₹355.89 crores in FY25 to ₹126.01 crores in FY26.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the 'Default' rating and insolvency proceedings indicate a high risk of total capital loss. Existing shareholders should closely monitor the CIRP process and any potential resolution plans, though equity holders typically face significant dilution in such scenarios.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
